IMNM Q4 2023 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$95M-2473.9% margin

Net Income

-$93M-2421.2% margin

EPS (Diluted)

$-4.22

QoQ Revenue Growth

+7.3%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$149M

Total Liabilities

$29M

Stockholders' Equity

$120M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$95M	-$8M	-1115.5%
Net Income	-$93M	-$8M	-1089.8%